PassITON试验:COVID-19恢复期血浆治疗住院成人的随机安慰剂对照临床试验方案
PassITON是一项在美国开展的多中心、安慰剂对照、盲法随机临床试验,旨在评估COVID-19恢复期血浆治疗有症状住院成人的临床疗效。计划入组1000例患者,主要终点为治疗14天后的7分类序贯量表临床状态,设计可检测主要终点OR≤0.73。
要点
- 纳入住院COVID-19且有呼吸道症状<14天的成人,1:1随机接受1单位恢复期血浆或安慰剂。
- 主要终点为治疗14天后7分类序贯量表评估的临床状态,关键次要终点包括死亡率和无氧天数。
- 试验计划入组1000例,设计可检测主要终点OR≤0.73。
核心结论
- 该试验旨在提供COVID-19恢复期血浆治疗住院成人疗效的高质量证据。
研究设计与样本
- 多中心、安慰剂对照、盲法、随机临床试验,在美国开展,计划入组1000例。
- 纳入住院COVID-19且有呼吸道症状<14天的成人,1:1随机接受1单位(200-399 mL)恢复期血浆或安慰剂。
- 恢复期血浆经SARS-CoV-2嵌合病毒中和试验证实具有中和功能,治疗盲法给药,随访28天。
关键数值与推荐
- 主要终点为治疗14天后7分类序贯量表评估的临床状态,该量表评估死亡率、呼吸支持和日常生活活动恢复。
- 关键次要终点包括死亡率和无氧天数。
- 试验设计可检测主要终点OR≤0.73。
临床怎么用
- 该试验结果将用于指导当前大流行中COVID-19住院患者的治疗决策。
- 试验数据可帮助判断是否需建立标准化基础设施以收集和分发恢复期血浆,为未来病毒大流行做准备。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Convalescent plasma is being used widely as a treatment for coronavirus disease 2019 (COVID-19). However, the clinical efficacy of COVID-19 convalescent plasma is unclear. METHODS: The Passive Immunity Trial for Our Nation (PassITON) is a multicenter, placebo-controlled, blinded, randomized clinical trial being conducted in the USA to provide high-quality evidence on the efficacy of COVID-19 convalescent plasma as a treatment for adults hospitalized with symptomatic disease. Adults hospitalized with COVID-19 with respiratory symptoms for less than 14 days are eligible. Enrolled patients are randomized in a 1:1 ratio to 1 unit (200-399 mL) of COVID-19 convalescent plasma that has demonstrated neutralizing function using a SARS-CoV-2 chimeric virus neutralization assay. Study treatments are administered in a blinded fashion and patients are followed for 28 days. The primary outcome is clinical status 14 days after study treatment as measured on a 7-category ordinal scale assessing mortality, respiratory support, and return to normal activities of daily living. Key secondary outcomes include mortality and oxygen-free days. The trial is projected to enroll 1000 patients and is designed to detect an odds ratio ≤ 0.73 for the primary outcome. DISCUSSION: This trial will provide the most robust data available to date on the efficacy of COVID-19 convalescent plasma for the treatment of adults hospitalized with acute moderate to severe COVID-19. These data will be useful to guide the treatment of COVID-19 patients in the current pandemic and for informing decisions about whether developing a standardized infrastructure for collecting and disseminating convalescent plasma to prepare for future viral pandemics is indicated. TRIAL REGISTRATION: ClinicalTrials.gov NCT04362176 . Registered on 24 April 2020.
引用
- Self WH, Stewart TG, Wheeler AP, et al. Passive Immunity Trial for Our Nation (PassITON): study protocol for a randomized placebo-control clinical trial evaluating COVID-19 convalescent plasma in hospitalized adults. Trials. 2021. PMID: 33743799. doi:10.1186/s13063-021-05171-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。